UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

AbbVie and Simcere Zaiming have announced an option-to-license agreement for the development of an investigational drug candidate, SIM0500. The humanised trispecific antibody is undergoing Phase I ...

The humanised trispecific antibody is undergoing Phase I clinical trials in the US and China in subjects with relapsed or refractory multiple myeloma (MM). Simcere Zaiming will gain an upfront ...

prompting the creation of multispecific antibodies, which include bispecific, trispecific, and tetraspecific antibodies. Among these, bispecific antibodies, capable of binding to two distinct epitopes ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Impressively, antibody fragments such as bispecific T-cell engager, bispecific killer cell engager, trispecific killer cell engager, tandem diabody, and dual-affinity-retargeting are showing exciting ...